- Curriculum Vitae
Date of birth: June 24th 1954
Place of birth: Milano, Italy
Mailing address: Department of Food and Drug, University of Parma, Parco Area Scienze 27/A, 43100 Parma, Italy
Education and Career
Graduated "Magna cum Laude" in Drug Chemistry and Technology at the University of Milan in 1979. Fellowship at the Department of Pharmacological Sciences directed by Prof Rodolfo Paoletti, University of Milan in 1979-84 and in 1986-92. Instructor and Visiting Scientist at the Baylor College of Medicine, Department of Medicine in Houston (TX; USA) directed by Prof. A.M. Gotto from 1984 to 1986 and about a total of 6 months in 1987 and 1988. Board certified in Experimental Pharmacology at the University of Milan in 1981. PhD in Experimental Medicine (Arteriosclerosis) in 1988. Associate Professor (1992-2001) and then Full Professor (since 2001) of Pharmacology at the University of Parma, Italy. Visiting Professor in 2004 (1 month) with an NIH grant at the Joseph Stokes Jr. Research Inst. Children's Hospital of Philadelphia (USA) in the laboratory of Prof. G. Rothblat. Responsible of the laboratory of Lipid Pharmacology at the Department of Food and Drug at the University of Parma (since 1992).
Prof Bernini has been invited at foreign institutes for seminars of scientific, special interest.
Most relevant national and international scientific collaborations:
Prof. GUIDO FRANCESCHINI: Università degli Studi di Milano, Dipartimento di Scienze per gli Alimenti, la Nutrizione e l’Ambiente, Milano, Italy; Prof. LAURA CALABRESI: Centro E. Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milano, Italy; Prof. SEBASTIANO CALANDRA: University of Modena and Reggio Emilia, Department of Biomedical, Metabolic and Neural Sciences, Modena, Italy; Prof. MARCELLO ARCA. Centro Aterosclerosi Dipartimento di Medicine Interne e Specialità Mediche, Policlinico Umberto I, Roma, Italy; Prof. GEORGE ROTHBLAT: Children's Hospital of Philadelphia Abramson Research Center, Philadelphia, USA; Prof. PAOLO PARINI: Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden; Prof. LAWRENCE RUDEL: Department of Pathology, Section on Lipid Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA; Prof. JOHN M. CHAPMAN: Hôpital de la Pitiè, Paris, France, Prof. WENDY JESSUP: Centre for Vascular Research, University of New South Wales, Sidney, Australia; KEMPEN HJ: The Medicines Company (Schweiz) GmbH, Zurich, Switzerland; MIRANDA VAN ECK: Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Gorlaeus Laboratories, Leiden University, Leiden, The Netherlands; MONIQUE MULDER: Department of Neurology, Erasmus MC, University Medical Center Rotterdam, the Netherlands; VON ECKARDSTEIN ARNOLD: Institute of Clinical Chemistry, University and University Hospital of Zurich, Switzerland; Competence Center for Integrated Human Physiology, University of Zurich, Switzerland; NOFER JR Center for Laboratory Medicine, University Hospital Münster, Germany.
Member of: International Society of Arteriosclerosis (IAS), European Lipoprotein Club (ELC), European Atherosclerosis Society (EAS), ULLA Consortium of European Pharmacy Schools, Italian Society of Pharmacology (SIF), Italian Society of Cardiovascular Research (INRC), Italian Society for Atherosclerosis Study (SISA), Italian Society of Cardiovascular Researches (SIRC).
European Lipoprotein Club (2007-2010)
Società Italiana per lo Studio dell’Aterosclerosi (2011-2013)
European Cooperation in Science and Technology (COST) (2010-2013)
President of the Emilia Romagna section of SISA (2004-2006).
President of the Emilia Romagna section of Società Italiana di Farmacologia (SIF) (from 2017).
Member of the Editorial Board of “Nutrition, Metabolism and Cardiovascular Diseases” (NMCD)
National Drug Project (1997), National Project sponsored by the University and Scientific and Technologic Research Minister (1998-2000; 2000-2002; 2005-2007), Fifth Framework Program of the European Commission (1999), FIRB (2001), Cofin (2000; 2005), Scientific project funded by Italian Group for Systemic Lupus Erythematosus Research (2010), Advance Diagnostics in Lipidology (ADSL) Regional Project (DiAL-ER) (2009-2011), European Cooperation in Science and Technology (COST) Action BM0904 HDL-From Biological Understanding to Clinical Exploitation (2010-2013), Research project founded by Fondazione CARIPLO entitled: “Investigating the role of pro-protein convertase subtilisin/kexin type 9 (PCSK9) released from smooth muscle cells on atherogenesis” (2012-0549) (2013); Scientific project funded by European Foundation for Alcohol Research (ERAB) (2014).
Scientific responsible for grants from Fournier, Glaxo, Recordati, Sigma Tau, Kowa, Hoffman La-Roche, Sienabiotech, Astrazenaca, Chiesi Farmaceutici, Circomed AG, Merck S&D, The Medicines Company, Rottapharm, AkademyPharma.
Additional fundings from: University of Parma, Spinner, Istituto Nazionale per la Ricerca Cardiovascolare (INRC).
Participations at national and international scientific meetings including invited lectures and Organizing Committees.
Member of Academic Senate, University of Parma (2012-2015).
President of the Spin Off Commission, University of Parma (2009-2011)
Coordinator of the supervision organ for the quality of the Department of Food and Drug, University of Parma (from 2017)
Delegate of the Department for research quality (from 2017)
Filing of patent application (Europe and USA) entitled “New MDR1 inhibitors for overcoming multidrug Resistance”. Number: PCT/EP2015/067795. Filing date: August 3, 2015
Filing of patent application: Italy (request n° 102016000102531), Europe (request n° 17196000.8) and United State (requested n° 15/729.728) for an eyes fluid administration device Eye Drop Aid (EDA)
Main research areas
Physiopathology and pharmacology of atherosclerosis and cholesterol metabolism. Prof. Bernini has a wide experience in evaluating cholesterol metabolic processes at cellular level and in vivo models applied research, aimed to the investigation of mechanisms regulating lipid homeostasis including its pharmacological or nutraceutical modulation for the prevention and therapy of cardiovascular disease. He provided major contributions to the elucidation of the antiatherogenic process of reverse cholesterol transport.
Bibliometric indicators related to publications and citations (Scopus)
Author of 151 papers in indexed international journals.
Number of total citations: 4584
Average Citations per Item 30.4
In the last 5 years (2013-2017), prof. Bernini published 22 articles in peer reviewed journals with impact factor. Among which, 54.5 % was in Q1, 36.4% in Q2 and 9.1% in Q3 of relevance.
Total impact factor (last 5 years): 97.85
Completion accademic year: 2020/2021
Completion accademic year: 2019/2020
- Course year: 1 - Second cycle degree - Medical, Veterinary anf Pharmaceutical Biotechnologies - A.Y.: 2019/2020
- Course year: 4 - Full cicle (5 years) - Pharmaceutical chemistry and technology - A.Y.: 2016/2017
Completion accademic year: 2018/2019
- Course year: 1 - Second cycle degree - Medical, Veterinary anf Pharmaceutical Biotechnologies - A.Y.: 2018/2019
- Course year: 4 - Full cicle (5 years) - Pharmaceutical chemistry and technology - A.Y.: 2015/2016
Completion accademic year: 2017/2018
- Course year: 1 - Second cycle degree - MEDICAL, VETERINARY AND PHARMACEUTICAL BIOTECHNOLOGIES - A.Y.: 2017/2018
- Course year: 4 - Full cicle (5 years) - Pharmaceutical chemistry and technology - A.Y.: 2014/2015
Completion accademic year: 2016/2017
- Course year: 1 - Second cycle degree - MEDICAL, VETERINARY AND PHARMACEUTICAL BIOTECHNOLOGIES - A.Y.: 2016/2017
- Course year: 4 - Full cicle (5 years) - Pharmaceutical chemistry and technology - A.Y.: 2013/2014
Completion accademic year: 2015/2016
- Course year: 1 - Second cycle degree - MEDICAL, VETERINARY AND PHARMACEUTICAL BIOTECHNOLOGIES - A.Y.: 2015/2016
Completion accademic year: 2014/2015
- Course year: 1 - Second cycle degree - MEDICAL, VETERINARY AND PHARMACEUTICAL BIOTECHNOLOGIES - A.Y.: 2014/2015
Completion accademic year: 2013/2014
- Course year: 1 - Second cycle degree - MEDICAL, VETERINARY AND PHARMACEUTICAL BIOTECHNOLOGIES - A.Y.: 2013/2014
- Second cycle degree HUMAN NUTRITION SCIENCES A.Y. 2020/2021
- DRUG SCIENCES A.Y. 2019/2020
- Full cicle (5 years) PHARMACEUTICAL CHEMISTRY AND TECHNOLOGY A.Y. 2019/2020
- Full cicle (5 years) PHARMACEUTICAL CHEMISTRY AND TECHNOLOGY A.Y. 2018/2019
- Full cicle (5 years) Pharmaceutical chemistry and technology A.Y. 2017/2018
- Full cicle (5 years) Pharmaceutical chemistry and technology A.Y. 2016/2017
- Full cicle (5 years) Pharmaceutical chemistry and technology A.Y. 2015/2016
- Second cycle degree HUMAN NUTRITION SCIENCES A.Y. 2020/2021
Year: 2019Author/s: Bergonzi C, Di Natale A, Zimetti F, Marchi C, Bianchera A, Bernini F, Silvestri M, Bettini R, Elviri L.
Activation profiles of monocyte-macrophages and HDL function in healthy women in relation to menstrual cycle and in polycystic ovary syndrome patientsYear: 2019Author/s: Tedesco S., Adorni M. P., Ronda N., Cappellari R., Mioni R., Barbot M., Pinelli S., Plebani M., Bolego C., Scaroni C., Bernini F., Fadini G. P., CIGNARELLA, ANDREA
Infusions of Large Synthetic HDL Containing Trimeric apoA-I Stabilize Atherosclerotic Plaques in Hypercholesterolemic RabbitsYear: 2019Author/s: Parolini C., Adorni M. P., Busnelli M., Manzini S., Cipollari E., Favari E., Lorenzon P., Ganzetti G. S., Fingerle J., Bernini F., Chiesa G.
ABCA1- and ABCG1-mediated cholesterol efflux capacity of cerebrospinal fluid is impaired in Alzheimer's diseaseYear: 2019Author/s: Marchi, Cinzia, Adorni, Maria Pia, Caffarra, Paolo, Ronda, Nicoletta, Spallazzi, Marco, Barocco, Federica, Galimberti, Daniela, Bernini, Franco, Zimetti, Francesca
High density lipoprotein function is reduced in patients affected by genetic or idiopathic hypogonadism.Year: 2019Author/s: Adorni MP, Zimetti F, Cangiano B, Vezzoli V, Bernini F, Caruso, Corsini A, Sirtori CR, Cariboni A, Bonomi M, Ruscica M